Wellness Expert Scopes Out the Future of Psychedelics and Cannabis

Pikovsky expects the cannabis industry to double in value by 2025

    facebook X logo linkedin

    The cannabis stock sector is booming, with legalization and decriminalization of marijuana in the United States and abroad rapidly expanding. In hot pursuit is the psychedelics industry, with legalization efforts initiated worldwide for a variety of different alternative medical treatments from this category. Investors want to know more about the cannabis and psychedelic investment opportunities from industry-leading experts.

    Today, we chatted with Alexej Pikovsky is the CEO and Founder of the Alphagreen Group. Alphagreen Group is a next-gen technology provider and e-commerce platform in the alternative health and wellness sector. The group began by launching alternative health and CBD marketplace alphagreen.io as the United Kingdom's CBD industry experienced speedy growth in 2020. The platform grew to the largest CBD marketplace in Europe within just six months As an investor in new alternative health brands, Pikovsky is also well versed in the potential growth of the psychedelics for mental health market and was a panelist at the Virtual Psychedelics Conference in 2020. 

    Schaeffer's: What are your thoughts on the cannabis industry right now? Where are the best places to find cannabis stocks worth investing in? And what kind of growth can investors expect to see in the future for the legalized marijuana industry?

    Alexej Pikovsky: Like with any nascent industry, investing in cannabis in the current climate is a high-risk venture with the potential for high rewards. If you are looking to invest in cannabis stocks, multi-state operators growing 30% year on year with high cash flow generation are your best bet for the next 12 months.

    If I had to give you my opinion on the top three stocks to snap up right now, I would go for Ayr Wellness Inc (CSE:AYR), Green Thumb Industries Inc (CSE:GTII), and Colombia Care Inc (CSE:CCHW). These companies are valued at low EBITDA multiples compared to other companies with similar growth rates and margins in the cannabis stock space.
    Overall, there is a considerable growth opportunity still to come - we expect the cannabis industry to double in value by 2025 as more states in the US and other countries decide to legalize cannabis for recreational use. We have just seen three political parties in Germany agree to legalize cannabis, and we expect other major nations to follow suit.

    Schaeffer's: Now, what about the psychedelics industry? What are your thoughts on that industry? Where are the best places to find psychedelics stocks worth investing in? And what kind of growth should investors expect to see in the future for the legalized and regulated psychedelics industry?

    Alexej Pikovsky: On the positive side, it’s easier to connect with IPO’s and leaders in the industry, seeing as psychedelics for healthcare are in the early stages of growth and the space is still relatively small. However, investing in this space is risky as most companies have no revenue and are, for the most part, based on predictions or some indication of clinical results. The majority of psychedelics for healthcare companies are listed in Canada due to their regulatory framework, which is far more agreeable for listings in the Cannabis and Psychedelic space. A fair amount of US companies list in Canada. We’ve seen an upswing in the trend for medical mushroom and psychedelics for health and feel there’s a huge potential for growth

    There are several pharmaceutical companies that are now developing hallucinogenic drugs for regulatory approval. Early scientific research suggests that compounds such as psilocybin are showing exciting promise for treating mental illnesses, including depression and schizophrenia. If further research concludes that hallucinogens are effective, there will be a surge of interest from investors, which will undoubtedly lead to exponential growth for Big Pharma.

    In terms of the recreational space, there is a long way to go. In most regions, psilocybin is a prohibited drug and is condemned by large quarters of most societies. But if research suggested that psilocybin was effective medically, we could see a push from advocates for legalization in the US and beyond. Despite this regulatory pushback in most countries, we have seen the success in the Netherlands of companies selling psychoactive truffles containing psilocybin, showing there is a big market waiting to be unlocked.

    *This article is published for purely informative purposes. Alphagreen Group's opinions are not necessarily a reflection in any way of those of Schaeffer's Investment Research. We publish information about companies in which we believe our readers may be interested. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalized advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as SIR's solicitation to effect, or attempt to effect, any transaction in a security. Investments in the securities markets, and especially in options and futures, are speculative and involve substantial risk. The information that we provide or that is derived from our website should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from SIR or derive from our website.*


    Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

    This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

    On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

    Start targeting gains like the ones our subscribers have seen recently, including:

    213.3% GAIN on AutoNation calls
    100.0% GAIN on Monster Beverage calls
    100.4% GAIN on Walgreens Boots Alliance puts
    100.4% GAIN on ON Semiconductor calls
    257.7% GAIN on Dell calls

    101.0% GAIN on Apollo Global Management calls
    103.6% GAIN on JP Morgan  Chase calls
    105.3% GAIN on DraftKings calls
    101.3% GAIN on Airbnb calls
    203.0% GAIN on Shopify calls
    102.0% GAIN on Cboe Global Markets calls
    100.9% GAIN on Boeing calls
    102.1% GAIN on Microsoft puts
    102.3% GAIN on First Solar calls
    101.5% GAIN on PulteGroup calls
    101.0% GAIN on Apple calls
    209.4% GAIN on NXP Semiconductors calls
    100.8% GAIN on Uber Technologies calls
    100.4% GAIN on Academy Sports and Outdoors puts
    102.2% GAIN on Trade Desk calls
    100.8% GAIN on DoorDash calls
    100.0% GAIN on Camping World Holdings puts
    100.0% GAIN on Cboe Global Markets calls
    100.2% GAIN on C3.ai calls
    238.5% GAIN on Oracle calls



    Rainmaker Ads CGI